This classification is of extreme importance both for BC prognosis as well as therapeutic targets, namely endocrine therapy for luminal A and B or anti-HER2 monoclonal antibodies against HER2+ breast cancer [9]. This evidence concerns the gene ERBB2 and breast cancer.